Common TitleCNAA3006
Official Title A Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of Abacavir (1592U89)/Zidovudine (ZDV)/Lamivudine (3TC) Versus the Combination of Zidovudine (ZDV)/Lamivudine (3TC) in HIV-1 Therapy-Experienced Pediatric Patients.
Phase Phase III
ClinicalTrials.gov NCT00002391
Treatments
Abacavir-Lamivudine-Zidovudine
Abacavir-Lamivudine-Zidovudine
Tradename:TrizivirOther Names:ABC-3TC-ZDVClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories PediatricsTreatment-ExperiencedDual Therapy
Funding
IndustryGlaxo Wellcome
References
- Sáez-Llorens X, Nelson RP Jr, Emmanuel P, et al. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. Pediatrics. 2001;107:E4.